Rockville, MD-based MacroGenics has raised $45 million in its third round of venture capital, bringing its total venture haul to date to $106 million. The Canadian venture group Ventures West led the round. MacroGenics' lead product is slated for a Phase II/III trial to begin later this year for Type 1 diabetes. MacroGenics also has earlier-stage prospects for cancer and autoimmune diseases. The biotech has 70 workers with plans to expand.
- here's the Washington Business Journal article on the round